RIPK1 Promotes Intrinsic and Extrinsic Resistance to Immunotherapy

Article navigation

Research Watch| July 06 2022

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2022

American Association for Cancer Research

Cancer Discov (2022) 12 (7): 1607.

Abstract

RIPK1 loss enhances immunotherapy by reshaping immune populations and poising tumor cells for killing.

2022

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.